FDA approved labeling changes on Vyvance, Shire's ADHD drug, extending the product's efficacy to 13 hours in children 6 to 12. According to a Shire release, the label changes represent the first and only oral ADHD stimulant treatment to have 13-hour postdose efficacy data for pediatric patients including in the labeling. Consumer and professional campaign materials in support of the label changes are currently in the works, according to a spokesperson.
Bayer Diabetes Care launched a new A1C monitor – A1CNow Selfcheck – enabling people with diabetes to check their A1C level at home. The product is now available without a prescription, and provides at-home results within five minutes, according to a statement.